Bailey & Ors v Glaxosmithkline (UK) Ltd

Factual and Procedural Background

The proceedings relate to claims brought by a group of Claimants against the Defendant, the manufacturer of the anti-depressant drug Paroxetine (known as Seroxat in the UK). The Claimants allege that Seroxat causes more severe withdrawal symptoms than other SSRIs, rendering it defective under the Consumer Protection Act 1987. The litigation began following increased interest after a 2002 BBC programme, with a Group Litigation Order made in 2007 covering generic issues and individual claims. The trial was originally fixed for 1 February 2011 but stalled due to the discharge of public funding in 2010 and subsequent appeals, resulting in a prolonged period of inactivity until January 2015 when public funding was finally withdrawn.

Following the withdrawal of funding, representation of the Claimants became uncertain, with various law firms involved over time. Fortitude Law was recognized as the Claimants' solicitors in July 2015, and 103 of the remaining 117 Claimants confirmed their intention to proceed. The adjourned Case Management Conference (CMC) was restored in August 2015 but was adjourned part heard in October 2015 to allow further information to be provided concerning funding, expert evidence, and case management. The court ordered the Claimants to provide detailed statements addressing directions sought, funding arrangements, and expert substitutions, with a further CMC scheduled for December 2015.

Legal Issues Presented

1. Does Seroxat have a greater capacity to cause adverse effects following discontinuation compared to other SSRIs?
2. Should the alleged defect be established by comparing Seroxat's adverse reactions against those of other prescription-only medicines?
3. If comparison is appropriate, should it be limited solely to other SSRIs?
4. Should a warning of such greater capacity have been included in the Defendant's product literature?
5. Can Seroxat be rendered defective under section 3 of the Consumer Protection Act 1987 if such greater capacity or failure to warn exists?
6. If defective, can the Defendant rely on the development risk defence under section 4(1)(e) of the 1987 Act?
7. Do the alleged adverse effects amount to actionable personal injury?
8. Has Seroxat caused the injuries alleged in individual cases?
9. What range of general damages should be awarded in individual cases?
10. Are the claims extinguished or statute-barred under sections 11A(3) or 11A(4A) of the Limitation Act 1980?

Arguments of the Parties

Claimants' Arguments

• Seroxat causes more severe withdrawal symptoms than other SSRIs, making it more difficult for users to discontinue.
• This alleged defect renders Seroxat defective under the Consumer Protection Act 1987.
• Seroxat was marketed and sold without adequate warnings about its withdrawal symptoms compared to other SSRIs.
• The Claimants seek to proceed to trial and require directions for new lead claims, disclosure, and expert evidence.
• The Claimants have secured commercial litigation funding and After The Event (ATE) insurance to cover adverse costs.
• Proposed substitution of experts includes replacing the psychopharmacology and statistics experts to continue litigation effectively.
• They acknowledge the need for further disclosure and expert report preparation, with a staged approach to case management and costs control.

Defendant's Arguments

• The Defendant denies the essential factual allegation that Seroxat causes more severe withdrawal symptoms.
• It contends that a prescription-only drug cannot be deemed defective merely by comparing adverse reactions with another drug.
• If Seroxat has more profound withdrawal symptoms or warnings were needed, it still would not render the drug defective under the 1987 Act.
• The Defendant asserts entitlement to the development risk defence under section 4(1)(e) of the 1987 Act.
• The Defendant challenges the adequacy of the Claimants' funding and the sufficiency of the proposed legal team.
• Concerns are raised about the impact of substituting experts and the potential costs and delays arising from new expert evidence and disclosure.
• The Defendant disputes the proposed length of trial and the number of lead cases, advocating for rigorous case management to prevent unmeritorious claims.

Table of Precedents Cited

Court's Reasoning and Analysis

The court undertook a comprehensive review of the procedural history, expert evidence, funding arrangements, and case management issues. It acknowledged the complexity and volume of expert reports and the importance of expert evidence in resolving the central factual issues. The court recognized the Defendant’s strong position in opposing continuation but noted that no application for strike out or summary judgment was before it.

Regarding funding, the court accepted the Claimants’ broad assertions of adequate commercial funding and ATE insurance but noted the lack of detailed supporting evidence. It emphasized that the adequacy of funding affects case management and must be monitored carefully.

The court considered the proposed substitution of experts on the Claimants’ side, concluding that the reasons for substitution were legitimate and that the changes would not amount to improper expert shopping. It acknowledged the impact on costs and trial preparation but accepted that new expert reports should provide independent views rather than mere adoption of predecessors’ reports.

On disclosure, the court anticipated a supplemental disclosure exercise covering extensive categories of documents since the previous disclosure closure, accepting the Defendant’s concerns about proportionality but noting the necessity of updated disclosure.

The court also reviewed the estimated trial length and the number of lead cases, expressing some skepticism about the Claimants’ reduced time estimates but accepting that six lead cases would suffice to address generic issues.

Ultimately, the court balanced the Defendant’s desire to halt the litigation against the Claimants’ right to proceed, concluding that it was premature to bring the proceedings to a permanent halt at this stage. The court resolved to adopt a step-by-step approach to case management, requiring further information, disclosure, and expert assessments before deciding on the future course of the litigation.

Holding and Implications

The court ADJOURNED the case management hearing part heard and directed that the Claimants provide detailed statements addressing the selection of lead claims, disclosure, funding arrangements, and expert substitutions by 27 November 2015. A further Case Management Conference was scheduled for mid-December 2015 to consider the additional information and submissions.

The court appointed Fortitude Law as Lead Solicitors under the Group Litigation Order to implement directions and oversee progress. It emphasized a cautious, cost-conscious, and staged approach to the litigation, aiming to avoid unnecessary prolongation and expense.

No final determination was made on the merits or the Defendant’s application to halt the proceedings. The decision preserves the Claimants’ ability to proceed subject to compliance with the court’s directions and further judicial scrutiny. The ruling does not establish new legal precedent but reflects established case management principles in complex group litigation.